Traws Pharma
trawspharma.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Targeting escape mutations in hematological cancers with first and best in class medicines.
News
Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones
Traws Pharma has structured up to $50 million of potential additional financing around specific regulatory and clinical milestones for its influenza program, directly connecting future capital availability to progress with tivoxavir marboxil and its plann
Read more
Report
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (
Read more
Report
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Read more
Report
Traws Pharma Delays 10-K Amid Financing Review
Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.
Read more
Report
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
--Traws Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 202
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Nikolay Savchuk
Director, Executive Officer
David Pauza
Executive Officer
Robert Redfield
Executive Officer
Mark Guerin
Executive Officer
Steven Fruchtman
Executive Officer
Werner Cautreels
Director, Executive Officer
Ramesh Kumar
Executive Officer, Director
Manoj Maniar
Executive Officer
Abraham Oler
Executive Officer
Richard Woodman
Executive Officer
M. Shoemaker
Director
Jack Stover
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Financials
Est. Annual Revenue
$500k
2018
Total raised
$15.8M
Latest round
Venture - Series Unknown
Funding rounds
3
Revenue
0% YoY
Estimate
Low-high range
Modelled from public signals, not audited accounts - read it as an order of magnitude.
| Year | Estimate | Low | High |
|---|---|---|---|
| 2017 | $500k | $1 | $1M |
| 2018 | $500k | $1 | $1M |